Theravance Biopharma (TBPH) Common Equity (2013 - 2026)

Theravance Biopharma (TBPH) has reported Common Equity for 14 consecutive years, with $290.6 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Common Equity rose 75.07% year-over-year to $290.6 million; the TTM figure through Mar 2026 stood at $290.6 million (up 75.07% YoY), while the FY2025 annual figure was $296.7 million, up 69.03% from the prior year.
• Common Equity eased to $290.6 million in Q1 2026 per TBPH's latest filing, from $296.7 million in the prior quarter.
• Across five years, Common Equity topped out at $480.6 million in Q3 2022 and bottomed at -$351.4 million in Q1 2022.
• Historically, Common Equity has averaged $194.2 million across 5 years, with a median of $224.8 million in 2025.
• Annual changes were most pronounced in 2022 — Common Equity jumped 248.51% — and 2023, when it sank 51.79%.
• Theravance Biopharma's Common Equity stood at $441.8 million in 2022, then tumbled by 51.79% to $213.0 million in 2023, then retreated by 17.58% to $175.5 million in 2024, then jumped by 69.03% to $296.7 million in 2025, then fell by 2.07% to $290.6 million in 2026.
• Business Quant data shows TBPH's Common Equity at $290.6 million in Q1 2026, $296.7 million in Q4 2025, and $232.7 million in Q3 2025.